PLMcCarthyBuffalo

Facile induction of immune tolerance by an interleukin-2–TGFβ surrogate agonist - Nature A fusion protein designed to comprise IL-2 and a helminth-derived TGFβ mimic activates IL-2 and TGFβ signalling pathways in IL-2 receptor-expressing T cells and induces stable antigen-specif...

www.nature.com/articles/s41...

The mechanosensitive adhesion G protein-coupled receptor 133 (GPR133/ADGRD1) enhances bone formation - Signal Transduction and Targeted Therapy Signal Transduction and Targeted Therapy - The mechanosensitive adhesion G protein-coupled receptor 133 (GPR133/ADGRD1) enhances bone formation

www.nature.com/articles/s41...

Adenoviral Inciting Antigen and Somatic Hypermutation in VITT | NEJM Vaccine-induced immune thrombocytopenia and thrombosis (VITT) is a rare prothrombotic complication that occurs after adenoviral vector–based vaccination against coronavirus disease 2019; in rare ca...

Adenoviral Inciting Antigen and Somatic Hypermutation in VITT | New England Journal of Medicine www.nejm.org/doi/10.1056/...

www.nature.com/articles/s41...

Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma Study marks the first positive Phase 3 study for mezigdomide and the second positive Phase 3 study for the Bristol Myers Squibb CELMoD program Bristol Myers Squibb (NYSE: BMY) today announced positive...

Bristol Myers Squibb - Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma news.bms.com/news/corpora...

Prasad Under Probe for Promoting Workplace Toxicity, Staffers Say Aside from creating a toxic work environment, CBER Director Vinay Prasad has also been accused of berating his staff and retaliating against reviewers who questioned his decisions.

www.biospace.com/fda/prasad-u...

Having some of the most thoroughly redacted thoughts of my life.

Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Mar 3, 2026--

Check out this link: www.galvnews.com/tncms/asset/editorial/4737592c-6261-5389-bf48-298bb55db22c
The FDA is behaving aberrantly.

Slowing down. Not a great PK.

Stanley becomes the second player in Sabres history to wear 64 (provided he doesn't change his mind before he plays a game) since David Moravec in '99.

Moravec played one game for Buffalo: Opening night of the 1999-2000 season against Detroit. It was the only game he ever played in North America.

Yes!

Trump Administration Live Updates: Vaccine Chief to Leave F.D.A.

www.nytimes.com/live/2026/03...

F.D.A. Faces Upset Over Denials of New Drugs

www.nytimes.com/2026/03/05/h...

Why does everything go out of its way to suck now?

A white work van in a parking lot that has "C&C Pest Control" written on the side

Did.. Did the Music Factory go out of business?

Pfizer CEO Albert Bourla on FDA official Vinay Prasad: 'We have a problem with the leadership of CBER' One of the most powerful voices in the biopharma industry, Pfizer CEO Albert Bourla, Ph.D., has weighed in with sharp criticism of the FDA’s Vinay Prasad, M.D., and his performance as the chief of | P...

www.fiercepharma.com/pharma/pfize...

investors.gilead.com/news/news-de....

Smooth operator.

Did more than grab Point which Lindy won't mind.

Nice recommendation from @joeyerdon.bsky.social

Antibody cocktails based on the occupationally acquired immunity of pediatricians neutralize and confer protection against RSV and hMPV Antibody cocktails derived from pediatricians cooperatively neutralize and protect rodents against RSV and hMPV by targeting conserved epitopes.

www.science.org/doi/10.1126/...

Hell yeah, I love my death snow banks

Nivolumab monotherapy following CAR-T therapy failure in MM or NHL rarely leads to clinical responses. However, for a minority of patients with myeloma, nivolumab leads to remarkably durable responses likely driven by endogenous T cells. Read in Blood ICT: buff.ly/7DOGA9h

Varnim-cel is a novel autologous CD19-directed CAR T-cell therapy with a murine A3B1 binder. Read in Blood ICT: buff.ly/ZsxD9I2

#history #scientifichistory #bloodjournal #hematology #editorinchief #eic #founder | Blood Journals Portfolio In honor of Blood’s 80th anniversary, we’re looking back at all the past Editors-in-Chief, starting with our Founding Editor! Dr. William Dameshek (1900–1969) was a pioneering American hematologist ...

In honor of Blood's 80th anniversary, we're looking back at all of the journal's past Editors in Chief. Today we're kicking off with our Founding Editor, Dr. William Dameshek (served 1946-1969). Learn more about him in this special feature: linkedin.com/feed/update/...

Reprogramming Listeria monocytogenes flavin metabolism to improve its therapeutic safety profile and broaden innate T-cell activation | mBio Listeria-based live-attenuated cancer vaccines represent a promising therapy in many different pre-clinical tumor models and in clinical trials. Enhancing its anti-cancer immunity and increasing its s...

journals.asm.org/doi/10.1128/...

Immune cells could be protected from ‘exhaustion’ by flipping genetic switches Some transcription-factor proteins govern decisions between functional and dysfunctional T-cell states.

Immune cells could be protected from ‘exhaustion’ by flipping genetic switches www.nature.com/articles/d41...

TCRγ constant usage tunes human γδ T cell antigen sensitivity, thymic programming, and peripheral function The human TCRγδ constant region modulates T cell activation and corresponds with T cell clonal expansion and function.

TCRγ constant usage tunes human γδ T cell antigen sensitivity, thymic programming, and peripheral function | Science Immunology www.science.org/doi/10.1126/...

Atlas-guided discovery of transcription factors for T cell programming - Nature A comprehensive atlas platform integrating transcriptional and epigenetic data enables more precise engineering of T cell states, accelerating the rational design of more effective cellular immunother...

www.nature.com/articles/s41...

Chimeric antigen receptor T cells against the IGHV4-34 B cell receptor specifically eliminate neoplastic and autoimmune B cells CAR T cells against the IGHV4-34 B cell receptor specifically target pathogenic B cells in both lymphoproliferative neoplasms and lupus.

Chimeric antigen receptor T cells against the IGHV4-34 B cell receptor specifically eliminate neoplastic and autoimmune B cells | Science Translational Medicine www.science.org/doi/10.1126/...